Literature DB >> 6782106

New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion.

M S Williams, R E Mayner, N J Daniel, M A Phelan, S C Rastogi, F M Bozeman, F A Ennis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6782106     DOI： 10.1016/s0092-1157(80)80006-0

Source DB:  PubMed          Journal:  J Biol Stand        ISSN： 0092-1157


× No keyword cloud information.
  14 in total

1.  Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Authors:  Surender Khurana; Christopher Larkin; Swati Verma; Manju B Joshi; Juan Fontana; Alasdair C Steven; Lisa R King; Jody Manischewitz; William McCormick; Rajesh K Gupta; Hana Golding
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

2.  Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.

Authors:  Felix Geeraedts; Vinay Saluja; Wouter ter Veer; Jean-Pierre Amorij; Henderik W Frijlink; Jan Wilschut; Wouter L J Hinrichs; Anke Huckriede
Journal:  AAPS J       Date:  2010-03-02       Impact factor: 4.009

3.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Authors:  Antoine Minne; Jamila Louahed; Sybille Mehauden; Benoît Baras; Jean-Christophe Renauld; Rita Vanbever
Journal:  Immunology       Date:  2007-05-22       Impact factor: 7.397

4.  Evaluation of Epic® label-free technology to quantify functional recombinant hemagglutinin.

Authors:  Lianlian Jiang; Maryna C Eichelberger
Journal:  Biol Proced Online       Date:  2015-03-09       Impact factor: 3.244

5.  Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss.

Authors:  Kathleen M Holtz; Pamela S Robinson; Erin E Matthews; Yoshifumi Hashimoto; Clifton E McPherson; Nikolai Khramtsov; Michael J Reifler; Jamal Meghrous; David G Rhodes; Manon M Cox; Indresh K Srivastava
Journal:  BMC Biotechnol       Date:  2014-12-24       Impact factor: 2.563

6.  Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.

Authors:  Galina M Vodeiko; Jerry P Weir
Journal:  Influenza Other Respir Viruses       Date:  2011-09-08       Impact factor: 4.380

7.  Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability.

Authors:  Elena Feshchenko; David G Rhodes; Rachael Felberbaum; Clifton McPherson; Joseph A Rininger; Penny Post; Manon M J Cox
Journal:  BMC Biotechnol       Date:  2012-10-30       Impact factor: 2.563

8.  Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

Authors:  Felix Geeraedts; Nadege Goutagny; Veit Hornung; Martina Severa; Aalzen de Haan; Judith Pool; Jan Wilschut; Katherine A Fitzgerald; Anke Huckriede
Journal:  PLoS Pathog       Date:  2008-08-29       Impact factor: 6.823

9.  A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.

Authors:  Falko Schmeisser; Anupama Vasudevan; Jackeline Soto; Arunima Kumar; Ollie Williams; Jerry P Weir
Journal:  Influenza Other Respir Viruses       Date:  2014-08-02       Impact factor: 4.380

10.  A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.

Authors:  Falko Schmeisser; Xianghong Jing; Manju Joshi; Anupama Vasudevan; Jackeline Soto; Xing Li; Anil Choudhary; Noel Baichoo; Josephine Resnick; Zhiping Ye; William McCormick; Jerry P Weir
Journal:  Influenza Other Respir Viruses       Date:  2016-01-29       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.